Trump administration will fund new research on controversial psychedelic drug ibogaine
The Trump administration has announced $4.9 million in funding to research the medical potential of ibogaine, a psychedelic drug, for treating PTSD in veterans. The initiative aims to establish manufacturing and study protocols, though the drug remains currently illegal in the U.S.
Why it matters
This represents a significant shift in federal drug policy and potential medical breakthroughs for treatment-resistant mental health conditions among veterans.
WASHINGTON (AP) — Federal officials on Thursday announced new funding to explore the medical potential of ibogaine, a controversial psychedelic drug championed by veterans, conservative lawmakers and podcasters aligned with President Donald Trump. Health Secretary Robert F. Kennedy Jr. said his department is awarding up to $4.9 million to prepare for the first U.S. studies of ibogaine for post-traumatic stress disorder, a hard-to-treat condition linked to higher suicide and substance abuse rates among veterans. The money will not go directly to patient research, Kennedy said, but to lay the groundwork needed to manufacture, dose and design studies of the drug. Ibogaine is made from a shrub native to West Africa. It can cause intense hallucinations, nausea, vomiting, tremors and sometimes deadly irregular heart rhythms. Ibogaine is currently illegal, in the same ultra-restrictive class as LSD, ecstasy and most other psychedelic drugs.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in